ZA882288B - Method of distinguishing between different types of obesity - Google Patents

Method of distinguishing between different types of obesity

Info

Publication number
ZA882288B
ZA882288B ZA882288A ZA882288A ZA882288B ZA 882288 B ZA882288 B ZA 882288B ZA 882288 A ZA882288 A ZA 882288A ZA 882288 A ZA882288 A ZA 882288A ZA 882288 B ZA882288 B ZA 882288B
Authority
ZA
South Africa
Prior art keywords
adipsin
obesity
distinguishing
different types
gain
Prior art date
Application number
ZA882288A
Other languages
English (en)
Inventor
Jeffrey S Flier
S Flier Jeffrey
Bruce M Spiegelman
M Spiegelman Bruce
Original Assignee
Beth Israel Hospital
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Dana Farber Cancer Inst Inc filed Critical Beth Israel Hospital
Publication of ZA882288B publication Critical patent/ZA882288B/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/044Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA882288A 1987-04-02 1988-03-30 Method of distinguishing between different types of obesity ZA882288B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3420387A 1987-04-02 1987-04-02

Publications (1)

Publication Number Publication Date
ZA882288B true ZA882288B (en) 1988-12-28

Family

ID=21874944

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA882288A ZA882288B (en) 1987-04-02 1988-03-30 Method of distinguishing between different types of obesity

Country Status (13)

Country Link
EP (2) EP0382720B1 (xx)
JP (1) JPH02503229A (xx)
AT (1) ATE80465T1 (xx)
AU (1) AU606946B2 (xx)
DE (1) DE3874543T2 (xx)
DK (1) DK675388D0 (xx)
ES (1) ES2046325T3 (xx)
FI (1) FI894592A (xx)
GR (1) GR3005716T3 (xx)
IL (1) IL85897A0 (xx)
NO (1) NO885360L (xx)
WO (1) WO1988007681A1 (xx)
ZA (1) ZA882288B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8087591A (en) * 1990-06-01 1991-12-31 W. Alton Jones Cell Science Center Mammalian adipogenic factors
EP1578367A4 (en) * 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2015138309A1 (en) 2014-03-13 2015-09-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for regulating pancreatic beta cell function using adipsin
DE102014107380A1 (de) 2014-05-26 2015-11-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür

Also Published As

Publication number Publication date
NO885360D0 (no) 1988-12-01
EP0382720A1 (en) 1990-08-22
EP0287509B1 (en) 1992-09-16
AU606946B2 (en) 1991-02-21
EP0287509A1 (en) 1988-10-19
ATE80465T1 (de) 1992-09-15
EP0382720A4 (en) 1991-01-02
DK675388A (da) 1988-12-02
IL85897A0 (en) 1988-09-30
DK675388D0 (da) 1988-12-02
DE3874543D1 (de) 1992-10-15
JPH02503229A (ja) 1990-10-04
WO1988007681A1 (en) 1988-10-06
DE3874543T2 (de) 1993-02-04
AU1591388A (en) 1988-11-02
EP0382720B1 (en) 1992-09-09
ES2046325T3 (es) 1994-02-01
FI894592A0 (fi) 1989-09-28
FI894592A (fi) 1989-09-28
NO885360L (no) 1989-02-01
GR3005716T3 (xx) 1993-06-07

Similar Documents

Publication Publication Date Title
WO1998027227A3 (en) Pharmacogenetic methods for use in the treatment of nervous system diseases
NZ284412A (en) Apolipoprotein E polymorphism and treatment of Alzheimer's Disease
Baly et al. Dissociation of insulin-stimulated glucose transport from the translocation of glucose carriers in rat adipose cells.
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
DE3681883D1 (de) System zum sammeln, behandeln und zurueckfuehren des blutes eines patienten.
EP1019072A4 (en) ASSISTANCE PROCESS FOR DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISM SYNDROME
EP0625991A4 (en) IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF FROM LEUKOCYTES OF THE HUMAN PERIPHERAL BLOOD.
EP0376251A3 (en) An anticoagulant substance obtained from urine
SE9201573D0 (sv) Use of igf-1
ATE142500T1 (de) Doppelsträngige rns zur korrektur von abnormalitäten von zirkulierenden immunkomplexen und der monozytenfunktion
ZA882288B (en) Method of distinguishing between different types of obesity
ZA92389B (en) Method for detection of anti-rna-antibodies
Nakamura et al. A novel variant of transthyretin (Glu89Lys) associated with familial amyloidotic polyneuropathy
DE3790139D2 (en) Antiparatypical antibodies, their use for detecting and treating auto-immune diseases
Scharf et al. Transverse myelitis with systemic lupus erythematosus
DE3572033D1 (en) Method for diagnosis of a.i.d.s.
Goldstein Carbamazepine treatment for stuttering.
Wallach et al. Interferon-induced proteins: biological functions and clinical applications
Digel et al. Induction of interferon gamma in leucocyte cultures of the peripheral blood of mice
SU943578A1 (ru) Способ определени суточной дозы гепарина
UA6102A1 (uk) Спосіб визначення індивідуальної чутливості хворих до кемантану при хронічному обструктивному бронхіті
KR890005277A (ko) 2본쇄 rna 부족 상태의 진단 및 치료방법
Herd et al. The Hurler syndrome: treatment of cultured Hurler fibroblasts with normal human serum
Greene et al. The effect of age on ranitidine pharmacokinetics.
Smyth Assessment of severely and profoundly handicapped persons: implications for programming